We selected two of these compounds, 109 and 136, that differ for overall potency and degree of specificity for HDAC3, both being higher for compound 109 (Figure 1), and tested them in FRDA patients' PBMC and in the KIKI mouse model. This evidence concerns the gene HDAC3 and Friedreich ataxia.